Vifor has agreed to acquire Sanifit Therapeutics and Inositec AG for a total combined deal value of EUR€395 M. From the deals, the company gains access to two treatments for vascular calcification – the Phase III candidate, SNF472, and Phase I-ready asset, INS-3001. The announcement comes at an unsteady time for Vifor’s nephrology pipeline, after the company reported disappointing results from a Phase III trial of its hepatocyte growth factor drug, ANG-3777.